Dianthus Therapeutics, Inc.
- DNTH
- NASDAQ
- Biotechnology
- Autoimmune Therapies
- Monoclonal Antibodies
- Clinical-Stage Biotech
$72.09
Today −3.27%Quote Oct 16, 2026, 08:00 PM UTC
−28.71%over the last month
Max drawdown −28.7%From 1-month high −28.7%3 months −28.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$4.03B
Quote Oct 16
Next earnings
Nov 5
Expected, not confirmed
Analyst target
$132.60
+83.9% from here
Floor
$70.57
2.1% below price
Where the price sits
11 analysts
Analyst range, low to high
$120.00$158.00
- Price $72.09
- Resistance $75.82
- Consensus $132.60
Analysts' average target sits about 84% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about DNTHPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
92
Founded
2019